文献速递妇科生殖医学

全基因组遗传分析揭示丝裂原活化蛋白激酶(MAPK)信号通路在子宫内膜异位症发病机制中的作用

Genome-wide genetic analyses highlight mitogen-activated protein kinase (MAPK) signaling in the pathogenesis of endometriosis.
PubMed 文献 · Hum Reprod · 2017-01-01

该研究利用国际内基因联盟的GWAS数据(3194例手术确诊子宫内膜异位症病例和7060例欧洲血统对照)进行通路富集分析,发现14条通路与子宫内膜异位症遗传关联富集,其中A期疾病(rAFS I/II)突出显示MAP3K4新变异,且MAPK相关通路在全部和A期疾病中显著关联,B期疾病则富集细胞外基质通路。

要点

  • A期子宫内膜异位症全基因组关联分析发现MAP3K4内新变异rs144240142(P=6.45×10-8,OR=1.71,95%CI=1.23-2.37)。
  • 全部子宫内膜异位症和A期疾病富集通路涉及整合素介导的MAPK激活和细胞内ERK/MAPK级联。
  • B期疾病富集细胞外基质核心蛋白聚糖和ECM糖蛋白通路,提示A/B期可能具有部分不同的因果病理生理。

核心结论

  • 与全部和特别是A期子宫内膜异位症相关的顶级通路涉及整合素介导的MAPK激活和下游细胞内ERK/MAPK,均参与细胞分裂、基因表达、细胞运动和存活控制。
  • B期疾病其他顶级富集通路包括对细胞外结构和生化支持重要的ECM糖蛋白通路。
  • 结果进一步支持微小/轻度(rAFS I/II)与中度/重度(rAFS III/IV)子宫内膜异位症至少部分具有不同因果病理生理的假说。

研究设计与样本

  • 利用国际内基因联盟GWAS数据进行通路分析,纳入3194例手术确诊子宫内膜异位症病例和7060例欧洲血统对照,基因型数据填充至1000 Genomes Phase three参考面板。
  • 分别对全部子宫内膜异位症病例及A期(rAFS I/II,n=1686)和B期(rAFS III/IV,n=1364)病例进行GWAS。
  • 使用MSigDB(包括BioCarta、KEGG、PID、SA、SIG、ST和GO)和PANTHER通路数据库,采用MAGENTA软件进行统计富集分析。

主要发现

  • A期子宫内膜异位症首次全基因组关联分析发现MAP3K4内新位点rs144240142(P=6.45×10-8,OR=1.71,95%CI=1.23-2.37),该SNP与B期疾病无关(P=0.086)。
  • MAP3K4在A期病例与对照的在位内膜中差异表达(P=3.8×10-4),但与B期疾病无关(P=0.26)。
  • 共识别14条富集遗传关联的通路(FDR-P<0.05)。
  • 与全部子宫内膜异位症相关的通路包括Grb2-Sos提供整合素与MAPK信号连接通路(P=2.8×10-5,FDR-P=3.0×10-3)、Wnt信号(P=0.026,FDR-P=0.026)和p130Cas连接整合素与MAPK信号通路(P=6.0×10-4,FDR-P=0.029);A期相关通路包括细胞外信号调节激酶(ERK)1 ERK2 MAPK(P=5.0×10-4,FDR-P=5.0×10-4);B期相关通路包括两个重叠的细胞外基质生物学通路——核心蛋白聚糖(P=1.4×10-3,FDR-P=0.013)和ECM糖蛋白(P=1.8×10-3,FDR-P=7.1×10-3)。
  • 候选基因研究获得的基因富集于白细胞介素信号通路(P=2.3×10-12)、凋亡信号通路(P=9.7×10-9)和促性腺激素释放激素受体通路(P=1.2×10-6),但这些通路未出现在基于GWAS数据的结果中。

局限性

  • 分析限制于可分配至通路的基因内/附近变异,排除基因间变异。
  • 分析限制于数据库中注册的基于基因的通路定义。
  • 分析限制于欧洲血统女性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Do genome-wide association study (GWAS) data for endometriosis provide insight into novel biological pathways associated with its pathogenesis? SUMMARY ANSWER: GWAS analysis uncovered multiple pathways that are statistically enriched for genetic association signals, analysis of Stage A disease highlighted a novel variant in MAP3K4, while top pathways significantly associated with all endometriosis and Stage A disease included several mitogen-activated protein kinase (MAPK)-related pathways. WHAT IS KNOWN ALREADY: Endometriosis is a complex disease with an estimated heritability of 50%. To date, GWAS revealed 10 genomic regions associated with endometriosis, explaining <4% of heritability, while half of the heritability is estimated to be due to common risk variants. Pathway analyses combine the evidence of single variants into gene-based measures, leveraging the aggregate effect of variants in genes and uncovering biological pathways involved in disease pathogenesis. STUDY DESIGN SIZE, DURATION: Pathway analysis was conducted utilizing the International Endogene Consortium GWAS data, comprising 3194 surgically confirmed endometriosis cases and 7060 controls of European ancestry with genotype data imputed up to 1000 Genomes Phase three reference panel. GWAS was performed for all endometriosis cases and for Stage A (revised American Fertility Society (rAFS) I/II, n = 1686) and B (rAFS III/IV, n = 1364) cases separately. The identified significant pathways were compared with pathways previously investigated in the literature through candidate association studies. PARTICIPANTS/MATERIALS, SETTING, METHODS: The most comprehensive biological pathway databases, MSigDB (including BioCarta, KEGG, PID, SA, SIG, ST and GO) and PANTHER were utilized to test for enrichment of genetic variants associated with endometriosis. Statistical enrichment analysis was performed using the MAGENTA (Meta-Analysis Gene-set Enrichment of variaNT Associations) software. MAIN RESULTS AND THE ROLE OF CHANCE: The first genome-wide association analysis for Stage A endometriosis revealed a novel locus, rs144240142 (P = 6.45 × 10-8, OR = 1.71, 95% CI = 1.23-2.37), an intronic single-nucleotide polymorphism (SNP) within MAP3K4. This SNP was not associated with Stage B disease (P = 0.086). MAP3K4 was also shown to be differentially expressed in eutopic endometrium between Stage A endometriosis cases and controls (P = 3.8 × 10-4), but not with Stage B disease (P = 0.26). A total of 14 pathways enriched with genetic endometriosis associations were identified (false discovery rate (FDR)-P < 0.05). The pathways associated with any endometriosis were Grb2-Sos provides linkage to MAPK signaling for integrins pathway (P = 2.8 × 10-5, FDR-P = 3.0 × 10-3), Wnt signaling (P = 0.026, FDR-P = 0.026) and p130Cas linkage to MAPK signaling for integrins pathway (P = 6.0 × 10-4, FDR-P = 0.029); with Stage A endometriosis: extracellular signal-regulated kinase (ERK)1 ERK2 MAPK (P = 5.0 × 10-4, FDR-P = 5.0 × 10-4) and with Stage B endometriosis: two overlapping pathways that related to extracellular matrix biology-Core matrisome (P = 1.4 × 10-3, FDR-P = 0.013) and ECM glycoproteins (P = 1.8 × 10-3, FDR-P = 7.1 × 10-3). Genes arising from endometriosis candidate gene studies performed to date were enriched for Interleukin signaling pathway (P = 2.3 × 10-12), Apoptosis signaling pathway (P = 9.7 × 10-9) and Gonadotropin releasing hormone receptor pathway (P = 1.2 × 10-6); however, these pathways did not feature in the results based on GWAS data. LARGE SCALE DATA: Not applicable. LIMITATIONS, REASONS FOR CAUTION: The analysis is restricted to (i) variants in/near genes that can be assigned to pathways, excluding intergenic variants; (ii) the gene-based pathway definition as registered in the databases; (iii) women of European ancestry. WIDER IMPLICATIONS OF THE FINDINGS: The top ranked pathways associated with overall and Stage A endometriosis in particular involve integrin-mediated MAPK activation and intracellular ERK/MAPK acting downstream in the MAPK cascade, both acting in the control of cell division, gene expression, cell movement and survival. Other top enriched pathways in Stage B disease include ECM glycoprotein pathways important for extracellular structure and biochemical support. The results highlight the need for increased efforts to understand the functional role of these pathways in endometriosis pathogenesis, including the investigation of the biological effects of the genetic variants on downstream molecular processes in tissue relevant to endometriosis. Additionally, our results offer further support for the hypothesis of at least partially distinct causal pathophysiology for minimal/mild (rAFS I/II) vs. moderate/severe (rAFS III/IV) endometriosis. STUDY FUNDING/COMPETING INTEREST(S): The genome-wide association data and Wellcome Trust Case Control Consortium (WTCCC) were generated through funding from the Wellcome Trust (WT084766/Z/08/Z, 076113 and 085475) and the National Health and Medical Research Council (NHMRC) of Australia (241944, 339462, 389927, 389875, 389891, 389892, 389938, 443036, 442915, 442981, 496610, 496739, 552485 and 552498). N.R. was funded by a grant from the Medical Research Council UK (MR/K011480/1). A.P.M. is a Wellcome Trust Senior Fellow in Basic Biomedical Science (grant WT098017). All authors declare there are no conflicts of interest.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Uimari O, Rahmioglu N, Nyholt DR, et al. Genome-wide genetic analyses highlight mitogen-activated protein kinase (MAPK) signaling in the pathogenesis of endometriosis. Hum Reprod. 2017. PMID: 28333195. doi:10.1093/humrep/dex024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。